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Abstract
Background Hemodynamic instability following the changeover
of vasoactive infusion pump (CVIP) is a common problem in the
intensive care unit. Several empiric methods are used to achieve
CVIP. We hypothesized that the variation in these procedures
could generate some morbidity. We sought to assess the
effects of the standardization of practice, as a quality
improvement program, on the CVIP-induced incidents.
Materials and methods We performed a prospective before-
and-after intervention study including all adult patients with a
diagnosis of cardiovascular failure who received a continuous
infusion of vasoactive drugs or inotropic drugs. After a baseline
preimplementation period (phase 1), a standardized 'quick
change method' of CVIP using two syringe drivers was
implemented in our intensive care unit (phase 2). Endpoints (rate
and distribution of incidents: variations of systolic blood
pressure >20 mmHg or heart rate >20 beats/min, and
arrhythmias) were registered in both 3-month phases.
Results We studied a total of 913 CVIP events (phase 1, 435
events; phase 2, 478 events) from 43 patients. Patient
characteristics were not significantly different among phases,
with a majority of the patients having septic shock. The
frequency of incidents was significantly (P < 0.0001) reduced
in phase 2 (5.9%, n = 28) versus phase 1 (17.8%, n = 78). This
effect was observed whichever catecholamine was used. More
than 98% of incidents were blood pressure variations, with a
similar distribution of the nature of incidents in both phases.
Conclusion The present study illustrates that adverse events
are common following CVIP, and illustrates the positive impact
of a quality improvement program to enhance inpatient safety
related to this current process of care.
Introduction
Circulatory failure is one of the most common organ dysfunc-
tions in patients admitted to the intensive care unit (ICU) [1].
These patients often require administration of intravenous
vasoactive or inotropic medications to optimize or support
their cardiovascular function [2]. These potent agents have a
very short half-life and are generally infused in high concentra-
tion with a low flow rate and a very narrow safety margin [3].
For these reasons, high-precision infusion pumps are recom-
mended to maintain a precise and constant flow rate in order
to achieve both constant plasma concentrations and effects
on the cardiovascular system [4]. Moreover, the limited syringe
capacity requires changeovers on a regular basis to ensure a
continuous supply of the drugs. Achieving hemodynamic sta-
bility is a major therapeutic goal for treating patients in shock
states. Difficulties in maintaining the hemodynamics during
and after changeovers of vasoactive infusion pumps (CVIPs)
are common problems [5-7]. Indeed, if a constant flow rate
cannot be ensured then serious complications, such as hemo-
dynamic instability and/or arrhythmia, may occur.
Several procedures are commonly used to achieve these infu-
sion exchanges, using either a single syringe driver [8] or two
syringe pumps with or without an overlapping period [5,6].
Nevertheless, it is not obvious to determine which of the two
CVIP managing methods is the most efficient [5-7]. There are
therefore no guidelines actually available. Despite a strong
demand from nurses in the ICU to standardize these health-
care procedures, in order to improve patients' safety, practices
vary widely.
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We hypothesized that the lack of standardization could result
in a greater number of adverse events related to CVIP. The aim
of the present study was to assess the influence of a quality
improvement program to help reduce the number of incidents
linked to this current care in the ICU.
Materials and methods
Initiating a quality improvement program
Following an internal audit in our institution, we identified CVIP
to be a daily problem. As recommended to overcome such dif-
ficulties [9-12], we decided to prioritize a quality improvement
program for CVIP in a nine-bed unit of our university-affiliated
adult medical ICU. Thanks to strong motivation in the staff, we
created a multidisciplinary work team with both designated
nurse and medical leaderships in order to improve healthcare
quality related to CVIP. Ethical approval was obtained from the
local institutional review board, and the study, including patient
(or family) information, was performed in accordance with the
ethical standards laid down in the 1964 Declaration of Hel-
sinki. Patients or their families gave informed consent. All
nurses and physicians were informed of the study protocol. No
change in hemodynamic management for cardiovascular dys-
function (including septic shock treatment) occurred in our
ICU during the study period.
Study design
Phase 1: environmental scan
The first prospective and observatory phase of the study was
conducted over a 3-month period. All adult patients suffering
from shock who received continuous infusion of catecho-
lamines (that is, dopamine, dobutamine, norepinephrine or
epinephrine) were observed according to this quality improve-
ment program. Cardiovascular dysfunction was defined by a
systolic arterial blood pressure <90 mmHg with signs of
peripheral hypoperfusion despite adequate fluid resuscitation,
and by a continuous infusion of vasopressor agents or ino-
tropic agents required to maintain systolic pressure ≥90
mmHg. In accordance with our routine clinical practices, all
patients who received these drugs had a central venous cath-
eter. Catecholamines were always infused with a minimal flow
rate of approximately 2 ml/hour. Patients were continuously
monitored, including their invasive arterial blood pressure. The
aim of this first phase was to record all the incidents (as
defined below) related to the CVIP. In this phase, nurses were
free to choose the method of changeover of CVIP they usually
practice.
Phase 2: standardization of changeover of vasoactive 
infusion pump
The second study phase was designed to standardize proce-
dures for CVIP and to change behaviors. Following phase 1,
during a 1-month period each nurse received a 1-day training
course including practical work. We chose as an effective
strategy the previously described 'quick change method',
using two syringe drivers, already known by the staff [5-8].
This handling consisted of loading the new infusion with a new
line into a new syringe pump, and priming the line when the
running infusion was about to finish. Both syringes were main-
tained at bed height. Nurses started the pump and chose a
high flow rate until a drop of the vasoactive drug appeared on
the end of the line, in order to avoid a startup delay. The nurses
then programmed the pump to the same rate and setting as
the previous infusion. The cap was then removed from the
spare port of the three-way stopcock and connected to the
new infusion pump. The nurses then turned the three-way
stopcock on to the new infusion, which closed the lumen of
the old infusion. Finally, the nurses had to disconnect the old
infusion and put a cap on the new spare port. Only one syringe
pump model (Pilot A2®; Fresenius Viale™, Brezin, France) was
used for this study, with 50 ml syringes (BD Plastipack®, Octe-
ville, France). The protocol was continuously available for con-
sultation in the ICU.
After this training period, as in phase 1, we recorded through-
out another 3-month period all incidents related to the CVIP in
patients treated with catecholamines.
Measurements
Baseline characteristics of the patients were registered: gen-
der, age, Simplified Acute Physiology Score II, type of admis-
sion and type of shock. Data related to CVIP were also
recorded: the catecholamine and its dose. The heart rate and
invasive systolic blood pressure were continuously recorded 5
minutes before and throughout CVIP on a monitor (Monitor
1165A®; Hewlett Packard™, Louisville, KY, USA). Baseline
hemodynamics were defined as the average of three measure-
ments preceding CVIP.
CVIP-induced incidents were defined as follows: a variation of
systolic blood pressure >20 mmHg if it occurs in the first 15-
minute period after the changeover; a variation of heart rate
>20 beats/min in the same time interval with regard to the
CVIP; and the occurrence of a documented atrial or ventricular
arrhythmia.
Statistical analysis
Assuming a CVIP-related incident frequency of 15% in the
control group (phase 1) based on prestudy observations, we
calculated that at least 736 CVIP events would be required for
the study to have 90% power to detect a 50% reduction in the
relative risk with a two-sided α level of 5%. Data are expressed
as counts and proportions or as the mean ± standard devia-
tion, as appropriate. Comparisons of categorical variables
were performed using a two-sided chi-square test or Fisher's
exact test, as appropriate. Continuous data were compared
using an unpaired Student's t test. Statistical significance was
defined as P < 0.05.Available online http://ccforum.com/content/11/6/R133
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Results
We studied 43 patients: 25 patients in phase 1 and 18
patients in phase 2. Characteristics of the patients are pre-
sented in Table 1. The most frequent cause of the acute circu-
latory failure was septic shock in medical patients from both
phases. Baseline characteristics were not significantly differ-
ent between groups (Table 1). Twenty-three patients (92%)
received vasopressor drugs (that is, dopamine, norepine-
phrine and epinephrine) in phase 1, and 10 of these patients
(43%) also received dobutamine. This was not significantly dif-
ferent in phase 2, with 15 patients (83%) and eight patients
(53%), respectively (P = not significant).
From these patients, 913 CVIP events were evaluated: 435
events in phase 1 and 478 events in phase 2. The number of
CVIP procedures per patient was not significantly different in
phase 1 (17.4 ± 23.4) versus phase 2 (26.5 ± 22.3) (P = not
significant). The distribution of changeovers according to the
catecholamines is presented in Table 2. Even though nore-
pinephrine and dobutamine were the main catecholamines
used in both phases, the distribution of all catecholamines was
significantly different (P < 0.05) – with more changeovers of
dobutamine and dopamine in phase 2 (45% and 22%, respec-
tively) than in phase 1 (37% and 14%, respectively), and more
changeovers of norepinephrine in phase 1 (48%) than in
phase 2 (32%).
The doses and flow rates for each inotropic/vasoactive drug
are presented in Table 3. Similar profiles were observed in
both phases excepted for the norepinephrine and dopamine
doses, which were significantly higher in phase 2 than in
phase 1. Concentrations of these two medicines were also
significantly higher in phase 2 versus phase 1, with differences
between both phases averaging 0.14 mg/ml and 1.06 mg/ml
for norepinephrine and dopamine, respectively (P < 0.05). The
other mean concentrations of catecholamines (that is, dob-
utamine and epinephrine) were not significantly different
between both phases of the study.
The number of patients who presented at least one CVIP-
related incident in phase 2 (11/18 patients, 61%) was
significantly (P = 0.02) reduced from phase 1 (23/25 patients,
92%). We recorded a total of 106 incidents during the study:
78 incidents in phase 1 and 28 incidents in phase 2. The fre-
quency of incidents was significantly lower in phase 2 than in
phase 1 (P < 0.0001), at 5.9% and 17.8%, respectively. In
addition, as presented in Table 2, this beneficial effect was
observed for each catecholamine, including norepinephrine.
As shown in Table 4, blood pressure variations were the most
frequent incidents we observed. No documented arrhythmia
was observed. The distribution of incidents nature did not sig-
nificantly differ (P = 0.18) among phases (Table 3). No fatal
event was related to CVIP.
Discussion
In the present study we demonstrate for the first time the pos-
itive effect of a quality improvement program on the incident
rate related to CVIP.
CVIP in the ICU is known to be responsible for specific mor-
bidity, including hemodynamic compromises [5-7]. The
Table 1
Baseline characteristics of patients
Phase 1 (n = 25) Phase 2 (n = 18) P value
Gender 0.60
Male 17 (68) 12 (66) -
Female 8 (32) 6 (34) -
Mean age 62 ± 14 60 ± 19 0.66
Type of admission 0.72
Medical 23 (92) 16 (88) -
Surgical 2 (8) 2 (12) -
Type of shock 0.66
Septic 22 (88) 16 (89) -
Cardiogenic 2 (8) 2 (11) -
Hemorrhagic 1 (4) 0 (0) -
Simplified Acute Physiology Score 
II
50 ± 22 53 ± 14 0.69
Data expressed as the number (%) of patients or as the mean ± standard deviation.Critical Care    Vol 11 No 6    Argaud et al.
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present work represents, to our knowledge, the largest survey
studying the adverse cardiovascular events related to CVIP,
even if the small number of patients could be considered a lim-
iting factor. Our results showed a high rate of incidents (about
18%) before standardization of the CVIP procedure. Systolic
blood pressure variations were the most frequent CVIP-
induced incidents and were more often than not related to
changeovers of vasoactive infusions. These findings are in
agreement with a previous ICU study from the United King-
dom, showing more than 35% of adverse effects to patient
blood pressure occur using three methods of epinephrine and
norepinephrine infusion pump changeovers [7]. In the present
survey, a wide majority of patients had septic shock and
required norepinephrine and/or dopamine to sustain hemody-
namics. These vasoactive drugs have adrenoreceptor-medi-
ated actions, especially powerful vasoconstriction effects (via
α-receptors) [3]. This can explain, in the setting of sepsis with
a large sensitivity to vasoconstrictive therapy, the dramatic
high rate of blood pressure variations we observed in our
population.
Adverse events related to CVIP can usually be explained by
multifactorial reasons [6]. First, the syringe pump/infusion sys-
tem can generate some flow-rate variability during continuous
intravenous infusions of potent drugs, which can induce sud-
den hemodynamic compromises in stable patients [13]. The
reason for these noncontinuous behaviors has been
extensively studied in recent clinical trials [14-20]. Low flow
rates should lead to oscillations in blood pressure, especially
when the set infusion rate is less than 1 ml/hour [14,15].
Similarly, a startup delay in fluid delivery as long as 30 minutes
can be observed because of the free play of the syringe [16],
or the presence of entrained air in the syringe that can consid-
erably affect both compliance of the infusion device and of the
occlusion alarm [17,18]. Moreover, a vertical displacement of
the syringe should change the hydrostatic pressure and alter
delivery of small infusate volumes [19,20]. For these reasons,
high-precision infusion pumps are required to perform CVIP in
the ICU [4].
A second reason for adverse events is that the choice of the
CVIP procedure can also affect the syringe pump output. To
achieve the relay, one or two syringe drivers can be used. In
vitro evidence suggested that the double-pump practice for
syringe changes provides better consistency in the dose deliv-
ery of inotropic medications [8]. In this case, either both
syringe drivers run together for a period of time or the ending
infusion is stopped while a new one is started. No study, how-
ever, was able to provide objective evidence as to which
method of CVIP was the most suitable [5,7]. The third, and by
no means the least important, issue is the lack of knowledge
on the part of the operators [21,22].
We conducted the present study to assess the influence of
the standardization of CVIP procedures on quality care. We
took all factors influencing the safety of CVIP, mentioned
above, into account. Particularly, according to our clinical
Table 2
Catecholamine changeover-induced hemodynamic incidents
Phase 1 Phase 2 P value
Dobutamine 11/162 (7) 3/214 (1) 0.006
Dopamine 21/62 (34) 10/106 (9) <0.001
Norepinephrine 46/207 (22) 15/155 (10) 0.002
Epinephrine 0/4 (0) 0/3 (0) -
Total 78/435 (18) 28/478 (6) <0.0001
Data expressed as the number of incidents/number of changeovers (%).
Table 3
Doses and flow rates for each vasoactive drug
Dose (μg/kg/min) Flow rate (ml/hour)
Phase 1 Phase 2 P value Phase 1 Phase 2 P value
Dobutamine 15.7 ± 6.2 14.6 ± 4.5 0.56 6.3 ± 2.2 5.3 ± 1.8 0.08
Dopamine 7.5 ± 5.9 9.9 ± 5.8 <0.01 4.5 ± 1.8 4.7 ± 2.0 0.53
Norepinephrine 1.8 ± 1.2 2.4 ± 1.5 <0.001 10.4 ± 5.9 11.9 ± 6.1 0.01
Epinephrine 3.5 ± 3.2 2.9 ± 0.9 0.79 13.0 ± 9.4 12.6 ± 4.0 0.95
Data expressed as the mean ± standard deviation.Available online http://ccforum.com/content/11/6/R133
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practices, we used high-precision syringe pumps and low-
compliance infusion devices. We also used drug concentra-
tions that obtain constant flow rates over 2 ml/hour, and main-
tained all syringe drivers at the same height. We chose the
well known (even so empiric) 'quick change method' using two
syringe drivers as an effective strategy to standardize our CVIP
practices. Indeed, it appeared that this procedure had at least
three advantages: 'the quick change method' minimized the
zero-infusion time using two pumps, was very quick and sim-
ple, and was less time-consuming for nurses.
Thanks to this quality improvement program in the ICU, by
changing staff behaviors, the intervention reduced the occur-
rence of adverse events by about 67%. We observed a similar
distribution of incidents in both phases of the study with a
wide majority of blood pressure variations. This dramatic
patient safety improvement was effective whichever catecho-
lamine was used, including vasoactive drugs.
Our positive results are all the more sound since doses of cat-
echolamines related to most incidents (that is, norepinephrine
and dopamine) are significantly higher in the second phase of
our study. After standardization, we still observed 6% CIVP-
induced incidents. We can speculate that part of these inci-
dents, related to devices and/or imperfections of the method,
cannot be cut down in the setting of critically ill patients. It
could be interesting, however, to compare the positive results
we obtained using the 'quick change method' with those we
could expect from new expensive smart pumps, with a modular
design, assisted by an internal computer, which can allow
automatic relays [23]. Further research is therefore needed to
refine the methods and to identify the most cost-effective
means of improving CVIP. Be that as it may, the present study
already provides some evidence to sustain a tremendous effort
to both educate medical staff and develop clinical guidelines
regarding the proper management of CVIP. In the future, it will
also be important to assess, on a regular basis, the preserva-
tion of our positive results, in agreement with the required
methodology of a continuous quality improvement program [9-
11,24,25].
Conclusion
In summary, the present study illustrates the high morbidity
rate related to CVIP in the ICU, and provides some evidence
to standardize these risky procedures to improve inpatient
safety. The study emphasizes also the necessity in the future
for a continuous quality improvement program, including
nurses in interdisciplinary teamwork, into general use of all ICU
healthcare practices.
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Nature of incidents
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Key messages
￿  Hemodynamic instability following CVIP is a common 
problem in the ICU.
￿  Without guidelines currently available, several empiric 
methods are commonly used to achieve changeovers of 
syringes.
￿  The present study illustrates the high rate of blood pres-
sure variations associated with the lack of standardiza-
tion of these procedures.
￿  Implementation of a standardized method, based on 
clinical evidence and local resources, could dramatically 
reduce adverse events linked to this practice.Critical Care    Vol 11 No 6    Argaud et al.
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nursing staff.
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